Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,824 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens.
Bannister WP, Mast TC, de Wit S, Gerstoft J, Wiese L, Milinkovic A, Hadziosmanovic V, Clarke A, Rasmussen LD, Lacombe K, Schommers P, Staub T, Zagalo A, Portu JJ, Tau L, Calmy A, Cavassini M, Gisinger M, Borodulina E, Mocroft A, Reekie J, Peters L; for the EuroSIDA study group. Bannister WP, et al. Among authors: clarke a. AIDS. 2022 Dec 1;36(15):2107-2119. doi: 10.1097/QAD.0000000000003332. Epub 2022 Jul 16. AIDS. 2022. PMID: 35848573
Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues.
Antinori A, Clarke A, Svedhem-Johansson V, Arribas JR, Arenas-Pinto A, Fehr J, Gerstoft J, Horban A, Clotet B, Ripamonti D, Girard PM, Hill AM, Moecklinghoff C. Antinori A, et al. Among authors: clarke a. AIDS. 2015 Sep 10;29(14):1811-20. doi: 10.1097/QAD.0000000000000778. AIDS. 2015. PMID: 26372387 Free article. Clinical Trial.
Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).
Milinkovic A, Benn P, Arenas-Pinto A, Brima N, Copas A, Clarke A, Fisher M, Schembri G, Hawkins D, Williams A, Gilson R; MiPEP Trial Team. Milinkovic A, et al. Among authors: clarke a. J Antimicrob Chemother. 2017 Jun 1;72(6):1760-1768. doi: 10.1093/jac/dkx062. J Antimicrob Chemother. 2017. PMID: 28369381 Free article. Clinical Trial.
Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?
Mocroft A, Laut K, Reiss P, Gatell J, Ormaasen V, Cavassini M, Hadziosmanovic V, Mansinho K, Pradier C, Vasylyev M, Mitsura V, Vandekerckhove L, Ostergaard L, Clarke A, Degen O, Mulcahy F, Castagna A, Sthoeger Z, Flamholc L, Sedláček D, Mozer-Lisewska I, Lundgren JD; EuroSIDA Study. Mocroft A, et al. Among authors: clarke a. AIDS. 2018 Jan 14;32(2):205-215. doi: 10.1097/QAD.0000000000001684. AIDS. 2018. PMID: 29112060
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.
Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group. Gatell JM, et al. Clin Infect Dis. 2019 Feb 1;68(4):597-606. doi: 10.1093/cid/ciy505. Clin Infect Dis. 2019. PMID: 29912307 Clinical Trial.
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M. Gupta SK, et al. Among authors: clarke ae. AIDS. 2019 Jul 15;33(9):1455-1465. doi: 10.1097/QAD.0000000000002223. AIDS. 2019. PMID: 30932951 Free PMC article.
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.
Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Raben D, Coll P, Antinori A, Nwokolo N, Rieger A, Prins JM, Blaxhult A, Weber R, Van Eeden A, Brockmeyer NH, Clarke A, Del Romero Guerrero J, Raffi F, Bogner JR, Wandeler G, Gerstoft J, Gutiérrez F, Brinkman K, Kitchen M, Ostergaard L, Leon A, Ristola M, Jessen H, Stellbrink HJ, Phillips AN, Lundgren J; PARTNER Study Group. Rodger AJ, et al. Among authors: clarke a. Lancet. 2019 Jun 15;393(10189):2428-2438. doi: 10.1016/S0140-6736(19)30418-0. Epub 2019 May 2. Lancet. 2019. PMID: 31056293 Free PMC article.
Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe.
Neesgaard B, Pelchen-Matthews A, Ryom L, Florence E, Peters L, Roen A, Svedhem V, Clarke A, Benfield T, Mitsura V, Moreno S, Beniowski M, Begovac J, Matulionyte R, Trofimova T, Elbirt D, Kundro M, Vullo V, Behrens G, Staub T, Ragone L, Vannappagari V, Lundgren J, Mocroft A; EuroSIDA study. Neesgaard B, et al. Among authors: clarke a. AIDS. 2019 Nov 1;33(13):2013-2024. doi: 10.1097/QAD.0000000000002320. AIDS. 2019. PMID: 31335807
3,824 results